obstructive

Arformoterol Tartrate ((R,R)-Formoterol tartrate) is the tartrate salt of arformoterol. Arformoterol is a long-acting beta-2 adrenergic agonist with bronchodilator activity[2].

Cilomilast (SB-207499) is a potent PDE4 inhibitor with an IC50 of approximately 110 nM, demonstrating anti-inflammatory activity and minimal central nervous system effects. Phase 3.

Lipopolysaccharides (LPS), derived from Escherichia coli O55:B5, are essential components of the outer membrane of Gram-negative bacteria. Composed of lipid A, a core oligosaccharide, and an O-specific polysaccharide, LPS exhibits strong immunogenicity. It activates immune cells via the TLR4 receptor, induces chemotactic cell migration and cytokine secretion, and helps maintain the integrity of the bacterial outer membrane, protecting against bile salts and lipid-based antibiotics. LPS is commonly used to establish inflammatory models, including arthritis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and gastrointestinal disease models.

PDE IV-IN-1 is a potent phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory activity for the treatment of asthma, chronic obstructive pulmonary disease and other inflammatory diseases, and is a potential compound for the study of depression.

IQB-782 is a mucolytic agent with mucolytic expectorant activity.IQB-782 inhibits thrombin-activating fibrinolytic inhibitor (TAFI), protects rats from tobacco smoke-induced respiratory obstruction, reduces the viscosity of gastric mucin suspensions in vitro, and may be useful in studies of obstructive lung disease.IQB-782 has been shown to reduce the viscosity of gastric mucin suspensions in vitro.

TD-5471 hydrochloride is a selective and potent long-acting human β2-adrenergic receptor agonist for the treatment of chronic obstructive pulmonary disease (COPD).

ZD-0892 is a selective and potent inhibitor of neutrophil elastase, targeting human neutrophil elastase and porcine pancreatic elastase with Kis of 6.7 nM and 200 nM, respectively.

Nemiralisib(GSK-2269557 free base) is an orally available, potent and specific PI3Kδ inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disease.

ASM-024, a potent nicotinic receptor agonist, is a small molecule synthetic piperazine compound that promotes different targets and signaling pathways of β2-adrenergic receptors mediating smooth muscle relaxation, and is a potential compound for the treatment of asthma and chronic obstructive bronchitis with anti-inflammatory activity.

Bedoradrine sulfate (MN-221 sulfate) is a novel, highly selective β2-adrenoceptor agonist for the treatment of asthma and chronic obstructive pulmonary disease.

Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease.

Alconil (Al 1567) is an aldose reductase inhibitor that may be used to study chronic obstructive pulmonary disease (COPD) and diabetes.

AWD 12-281 is a selective phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory and bronchodilator activity used in the study of chronic obstructive pulmonary disease (COPD).

GSK233705 (Darotropium bromide) is a muscarinic receptor antagonist used in conjunction with the prevention and treatment of chronic obstructive pulmonary disease (COPD) and asthma in humans.

Milveterol HCl is a long-acting β(2) -adrenergic receptor agonist for the potential treatment of chronic obstructive pulmonary disease (COPD).

PF-03635659 is a potent and long dissociative half-life muscarinic M3 antagonist (Ki: 0.2 nM) that shows potential for the treatment of chronic obstructive pulmonary disease (COPD).

Ronomilast (ELB353) can be used in the study of obstructive pulmonary disease.

Tanimilast (CHF-6001) is a novel, potent, and selective phosphodiesterase 4 inhibitor with an IC50 value of 0.026 ± 0.006 nM. It exhibits potent anti-inflammatory activity and is indicated for topical use in the lungs. Tanimilast was studied for its effects on obstructive lung disease.

PF 00356231 is a selectivity inhibitor MMP-12 and can be used in studies about the treatment of emphysema and chronic obstructive pulmonary disease (COPD).

Bedoradrine (MN-221) free base is a novel, highly selective β2-adrenoceptor agonist for the treatment of asthma and chronic obstructive pulmonary disease.

β2AR M-receptor agonist-2 is a dual-function compound acting as a muscarinic antagonist and β2 adrenoceptor agonist (MABA). It demonstrates significant activity towards the β2 adrenoceptor with an EC50 of 3.7 nM and exhibits affinity for the human cloned M3 receptor with a Ki of 0.73 nM. This potent bronchodilator holds potential for research in chronic obstructive pulmonary disease (COPD) treatment.

PF-4348235 HCl (β2AR M-receptor agonist-2 HCl) is a muscarinic M3 receptor antagonist (Ki: 0.73 nM) and β2 adrenergic receptor agonist (MABA, EC50: 3.7 nM). PF-4348235 HCl is also a bronchial BM213 acetate is a bronchodilator used to study cardiovascular and respiratory diseases such as chronic obstructive pulmonary disease (COPD).

JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.

Tiquizium has effective Antimuscarinic effect, and causes significant bronchodilation in patients with chronic obstructive pulmonary disease.